Purpose: To examine and compare the perioperative outcomes of laparoscopic adrenalectomy (LA) and to determine its efficacy in patients with nonfunctioning adrenal adenomas (NFA) and subclinical Cushing syndrome (SCS).
INTRODUCTION
Most adrenal incidentalomas are nonfunctioning adrenal adenomas (NFA) without classical clinical signs and symptoms that are commonly observed with glucocorticoid hypersecretion. 1 Subclinical Cushing syndrome (SCS) is also a common endocrine disease with an estimated incidence of approximately 20% in patients presenting with adrenal incidentalomas. 2 The 3 criteria commonly used to diagnose SCS are: (1) incidental detection of an adrenal adenoma using an imaging modality, (2) no clear phenotypic findings associated with Cushing syndrome, (3) subtle biochemical abnormalities such as adrenocorticotropic hormone (ACTH)-independent secretion of cortisol. 3 Patients with SCS do not demonstrate the typical clinical signs and symptoms of Cushing syndrome (CS), and a majority may demonstrate nonspecific findings including hypertension, dyslipidemia, osteoporosis, and glucose intolerance. 4 Although undeniably, adrenalectomy is the treatment of choice for the management of CS, optimal management of NFA and SCS remains a controversial issue with a lack of consensus in terms of conservative and/or surgical treatment. 2, 5 Although a few patients presenting with NFA demonstrate mild elevation of cortisol secretion without any symptoms of overt CS, indicating a state of SCS, only a small percentage of patients with SCS progress toward the development of overt CS. 6 Thus, the benefit of adrenalectomy for patients with NFA or SCS remains a controversial issue. A few authors have claimed that surgical therapy to treat these patients is associated with a higher risk of perioperative morbi-mortality than is observed with conservative therapy. However, a few others have reported that laparoscopic adrenalectomy (LA) is followed by normalization/improvement in the adverse metabolic profile noted in patients with NFA and SCS. 4, 7, 8 A number of small-scale studies have been performed in patients with either NFA or SCS; however, few studies have compared the effects of a LA directly in patients with NFA and SCS. We examined the perioperative outcomes of LA to determine its efficacy in patients with NFA and SCS, focusing on a comparison of the postoperative metabolic improvement observed between these groups.
MATERIALS AND METHODS

Study Population
We retrospectively obtained and evaluated the clinical data of 79 consecutive patients who underwent LA for the treatment of either SCS (n=44) or NFA (n=35) and who were regularly 
Study Design
All patients underwent diagnostic computed tomography.
Biochemical and endocrine evaluation of adrenal function was performed using the following laboratory tests for estimation All patients were followed-up at 1, 3, 6, and 12 months and Values are presented as median (interquartile range) or number (%). SCS: subclinical Cushing' syndrome, NFA: nonfunctioning adrenal tumor, LESS-A: laparoendoscopic single-site adrenalectomy, CLA: conventional laparoscopic adrenalectomy. 
Statistical Analysis
The primary endpoint was an improvement in metabolic abnormalities. A descriptive analysis of patient characteristics was performed, and the data were presented as median values with interquartile range (IQR) or a percentage (%) of events.
The Student t-test (for continuous variables) and the chi-square test (for categorical variables) were used to determine the statistical significance between groups. A p-value of ＜0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). Table 1 shows the baseline demographic data and perioperative outcomes. Additionally, the pathologic results of NFA are summarized in Supplementary Table 1 11.4%, respectively), hypertension (59.1% vs. 34.3%, respectively), and dyslipidemia (43.2% vs. 14.3%, respectively) ( Table 2) . No statistically significant difference was observed in the occurrence of overweight (BMI ≥ 25 kg/m 2 ) between the groups (Table 2) . We assessed the postoperative metabolic profile (Table 3) 
RESULTS
DISCUSSION
Given the variability in diagnostic criteria and optimal management of SCS, the most appropriate treatment for SCS patients remains a highly controversial issue, 10 although a few studies provide evidence that surgical treatment may be associated with a positive effect on the long-term clinical and metabolic outcomes in patients with SCS. [11] [12] [13] [14] [15] However, the limitations of most studies cannot be ignored including multiple/diverse definitions of SCS, a high degree of variability in the definition of study end-points and surgical outcomes, and uncontrolled study designs. 2 In this study, we reported that LA was an effective and safe treatment modality for the management of patients with SCS, particularly because it was not asso- In contrast to these findings, the Semmelweis University group analyzed 125 patients with NFA, and clearly noted that surgical treatment failed to normalize or improve the abnormal metabolic profile observed in these patients. 5 They also indicated that adrenalectomy did not reduce the rates of atherosclerosis-related morbi-mortality in patients with NFA. 5 Furthermore, an adrenalectomy was observed to be associated with a risk of postoperative adrenal insufficiency of the adrenal remnant, requiring cortisol replacement therapy. 17 A recent systematic review of 28 selected papers described that postoperative adrenal insufficiency was observed in 65.3% among 248 patients with SCS. 
CONCLUSIONS
In summary, our results demonstrated that LA was an effective and safe option to treat patients with SCS, particularly because it was associated with no significant perioperative complications and significant postoperative improvement in metabolic abnormalities such as hypertension, diabetes, dyslipidemia and obesity. However, LA was not observed to show beneficial effects in correcting/improving the metabolic profile in patients presenting with NFA. Our study offers valuable information to determine an optimal therapeutic strategy for the management of patients with SCS or NFA who present with metabolic manifestations.
